Health AI Central
Peer-Reviewed Publication
Sci Rep2026May 15, 2026Journal Article

Venous and arterial thromboembolic events after COVID-19 during the Omicron period in three European countries.

Xintong Li1, Annika M Jödicke1, Albert Prats-Uribe1, Antonella Delmestri1, Katia Verhamme2, Mees Mosseveld2, James T Brash3, Dina Vojinovic4, Anna Palomar-Cros5, Laura Pérez Crespo5, Talita Duarte-Salles2,5, Marek Oja6, Raivo Kolde6, Edward Burn1, Denise Umuhire7, Daniel R Morales7,8, Martí Català9
1Health Data Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom.
2Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
3IQVIA, Real world Solutions, London, United Kingdom.
4IQVIA, Real World Solutions, Amsterdam, The Netherlands.
5Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
6Institute of Computer Science, University of Tartu, Tartu, Estonia.
7European Medicines Agency, Amsterdam, The Netherlands.
8Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
9Health Data Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom. m.catalasabate@darwin-eu.org.
PubMed PMC DOI PDF

Abstract

Patients with earlier SARS-CoV-2 variants are at increased risk of venous and arterial thromboembolic (VTE, ATE) events. Here we aimed to contextualise the incidence of thromboembolic events among patients with COVID-19 during the Omicron period. We conducted a population-based cohort study using electronic health records from the UK (CPRD GOLD), the Netherlands (IPCI), and Spain (SIDIAP) within t…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.